Hydroxocobalamine Hcl Cf (Hydroxocobalamin Chloride)

Hydroxocobalamin chloride supplies bioavailable cobalamin that acts as a cofactor for enzymes such as methionine synthase and methylmalonyl‑CoA mutase, supporting DNA synthesis and fatty‑acid metabolism. In cyanide poisoning, it directly binds cyanide ions to form cyanocobalamin, which is then eliminated, reducing toxic cyanide levels.

The specific dose and dosing schedule of Hydroxocobalamine Hcl Cf are determined by the prescribing clinician based on the patient’s condition, severity, and clinical response. Healthcare professionals should follow local guidelines and product labeling when prescribing.

Safety data for Hydroxocobalamine Hcl Cf in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Hydroxocobalamine is a natural form of vitamin B12 with a longer plasma half‑life compared with cyanocobalamin, making it useful for sustained correction of deficiency and for cyanide detoxification. Unlike cyanocobalamin, it can directly bind cyanide, offering an advantage in acute poisoning scenarios.

Hydroxocobalamine Hcl Cf should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken, and it should remain in its original packaging until use to maintain stability.

The medication is supplied as an injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically into a large muscle such as the gluteus or into subcutaneous tissue, according to the prescriber’s instructions.

Serious adverse reactions, although rare, include anaphylaxis, severe hypotension, Stevens‑Johnson syndrome, hemolytic anemia, thrombocytopenia, and acute renal failure. Immediate medical attention is required if any of these symptoms develop after administration.

Patients with known hypersensitivity to hydroxocobalamin, its salts, or any excipients in the formulation should not receive the product. Caution is also advised for individuals with severe renal impairment or those who have experienced severe allergic reactions to other cobalamin preparations.